Abstract
Background: Resveratrol's structural similarity to commercialized anti-breast cancer medications such as Tamoxifen underlines its potential as a promising option for developing successful anti-breast cancer drugs. However, the pharmacokinetic issues associated with resveratrol, such as its low bioavailability, have piqued the attention of researchers in developing novel derivatives.
Methods: A novel phytoalexin derivative, RsvD1, was successfully synthesized using resveratrol extracted from green grape peels as a precursor to investigate its anti-breast cancer efficacy on Estrogen receptor (ER) positive and negative breast cancer cells.
Results: The comparative analysis revealed that RsvD1 exhibited remarkable radical scavenging ability (IC50 = 2.21 μg/mL), surpassing the control, Trolox (IC50 = 6.3 μg/mL). Furthermore, RsvD1 demonstrated enhanced and selective antiproliferative activity against ER-positive MCF-7 cells (IC50 = 20.09 μg/mL) compared to resveratrol, the parent molecule (IC50 = 30.90 μg/mL). Further investigations unveiled that RsvD1 induced apoptosis and DNA damage in MCF-7 cells, leading to cell cycle arrest at the G0/G1 phase after 24 hours of incubation. RTqPCR gene expression analysis indicated that RsvD1 down-regulated the CAXII (ER-dependent) genes. In silico predictions demonstrated that RsvD1 possesses promising potential as a drug candidate due to its drug-like characteristics and favourable ADMET profile. Moreover, molecular docking studies provided insights into the theoretical binding mode between RsvD1 and ERα protein.
Conclusion: The study highlights the therapeutic potential of the synthesized resveratrol derivative, RsvD1, positioning it as a promising scaffold for developing novel analogues with improved therapeutic properties and selectivity, specifically targeting ER+ breast cancer cells. Moreover, the compound's non-cytotoxic yet antiproliferative properties, coupled with its capability to induce programmed cell death and cell cycle arrest, enhance its potential as a highly effective drug candidate. As a result, this paves a promising path for the development of innovative and selective inhibitors targeting ER+ breast cancer with enhanced efficacy.
Graphical Abstract
[http://dx.doi.org/10.3390/nu8080515] [PMID: 27556486]
[http://dx.doi.org/10.1002/ardp.202000044] [PMID: 32342549]
[http://dx.doi.org/10.31925/farmacia.2023.1.16]
[http://dx.doi.org/10.3109/13697137.2014.937688] [PMID: 24978400]
[http://dx.doi.org/10.1139/bcb-2014-0136] [PMID: 26305052]
[http://dx.doi.org/10.3390/ijms140815655] [PMID: 23896596]
[http://dx.doi.org/10.1016/j.foodchem.2018.03.085] [PMID: 29739593]
[http://dx.doi.org/10.31925/farmacia.2022.3.5]
[http://dx.doi.org/10.3390/ijms21155244] [PMID: 32721999]
[http://dx.doi.org/10.31788/RJC.2023.1618114]
[http://dx.doi.org/10.22159/ijap.2023v15i4.45811]
[http://dx.doi.org/10.2174/1573407219666230511150434]
[http://dx.doi.org/10.1021/jf960281n]
[http://dx.doi.org/10.1016/0022-1759(83)90303-4] [PMID: 6606682]
[http://dx.doi.org/10.1016/0014-4827(88)90265-0] [PMID: 3345800]
[http://dx.doi.org/10.1007/BF02773401]
[http://dx.doi.org/10.1002/jcc.21256] [PMID: 19399780]
[http://dx.doi.org/10.1038/nsb1203-980] [PMID: 14634627]
[http://dx.doi.org/10.1093/nar/gkab294] [PMID: 33950214]
[http://dx.doi.org/10.1093/nar/gkab255] [PMID: 33893803]
[http://dx.doi.org/10.3390/ph15091061] [PMID: 36145282]
[http://dx.doi.org/10.1016/j.ejmech.2008.09.023] [PMID: 18976835]
[http://dx.doi.org/10.1186/1756-0500-4-3] [PMID: 21211020]